Toward rational management of patent ductus arteriosus: ductal disease staging and first line paracetamol

Arvind Sehgal, Itamar Nitzan, Mohan B. Krishnamurthy, Pramod Pharande, Kenneth Tan

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


Aims: To study paracetamol (PCM) use as first line therapy for significant patent ductus arteriosus (sPDA) closure, stratified by echocardiography. Methods: In this retrospective observational study, a prepublished score comprising PDA size and velocity, PDA:left pulmonary artery ratio, diastolic flow in main and LPA, LA:Ao ratio and left ventricular:aortic ratio were included for shunt severity. Successful closure was defined a priori as closure or ≥50% reduction in score. Comparisons were made between infants with sPDA who were treated and not treated. Results: During November 2017–2018, 227 infants from 23 to 31+6 weeks’ gestational age (GA) were admitted; 50 (22%) infants were diagnosed with PDA, 32 treated with PCM, overall treatment rate of 32/227 (14%). Successful therapy was noted in 23/32 (72%) and was higher when treated at ≤7 days (80 versus 68%, p =.68), in infants >26 weeks GA (62.5 versus 100%, p =.07) and BW >1000 g (65.4 versus 100%, p =.14). Univariate analysis noted statistical significance only for GA. Eighteen infants were managed conservatively. Treated infants had a lower GA and BW, higher composite ECHO score (14.4 ± 0.5 versus 19 ± 0.4, p <.001). Conclusions: Composite scoring helped reduce exposure, and focus more on infants with lower GA and BW with greater shunt severity.

Original languageEnglish
Pages (from-to)3940-3945
Number of pages6
JournalThe Journal of Maternal-Fetal and Neonatal Medicine
Issue number23
Publication statusPublished - 2 Dec 2021


  • Echocardiography
  • paracetamol
  • patent ductus arteriosus
  • score
  • staging

Cite this